Pseudoephedrine-Induced Hypertension Leading to Unnecessary Antihypertensive Therapy

Patient Background

Adam Smith is a 62-year-old male with a medical history of seasonal allergic rhinitis, hyperlipidaemia, and mild osteoarthritis. He had no previous diagnosis of hypertension and was not receiving antihypertensive therapy. His blood pressure had historically remained within an acceptable range, typically 122–130 / 74–82 mmHg.

With the onset of spring, Adam developed worsening seasonal allergy symptoms characterized by sneezing, nasal congestion, rhinorrhoea, and itchy, watery eyes. To provide combined antihistamine and decongestant therapy, he was started on Allegra-D, containing fexofenadine and pseudoephedrine.

Clinical Presentation

Adam experienced substantial improvement in his allergy symptoms after starting Allegra-D. However, several weeks later, during a routine clinical review, his blood pressure was found to be 152/92 mmHg, representing a significant increase from his previous readings.

The elevated blood pressure was interpreted as newly developed hypertension, and lisinopril 10 mg once daily was initiated.

Two months later, his blood pressure had improved modestly but remained elevated at 148/88 mmHg. Rather than investigating a potentially reversible cause of the hypertension, the lisinopril dose was increased. Despite dose escalation, subsequent blood pressure measurements remained above the desired target, prompting the addition of amlodipine 5 mg once daily.

At this stage, Adam was receiving two antihypertensive medications to manage elevated blood pressure that had developed shortly after the introduction of pseudoephedrine-containing allergy therapy.

Clinical Issue Identified

A comprehensive medication review identified pseudoephedrine contained within Allegra-D as a potentially reversible contributor to Adam’s newly elevated blood pressure.

Pseudoephedrine is an indirectly acting sympathomimetic decongestant that promotes norepinephrine-mediated adrenergic activity. Stimulation of predominantly α-adrenergic receptors in vascular smooth muscle produces vasoconstriction, including constriction of vessels within the nasal mucosa responsible for its decongestant effect. Systemic sympathomimetic activity, however, can also increase peripheral vascular resistance, blood pressure, and heart rate in susceptible individuals.

The temporal relationship was clinically important: Adam had previously demonstrated consistently controlled blood pressure, but sustained elevations emerged after starting pseudoephedrine.

Rather than initially considering a medication-induced elevation in blood pressure, the abnormal readings were treated as a new chronic disease, resulting first in lisinopril initiation and subsequently in additional antihypertensive therapy. This pattern represents a prescribing cascade, in which an adverse effect of one medication is misinterpreted as a new medical condition and treated with additional medication.

Pharmacist Intervention and Clinical Management

Identify the potential medication-related cause

• The pharmacist should review the timing of Adam’s blood pressure elevation in relation to the initiation of Allegra-D and recognize pseudoephedrine as a potential contributing factor.

• Other reversible contributors to elevated blood pressure should also be assessed, including NSAID use, excessive caffeine or alcohol intake, corticosteroids, adherence issues, and measurement technique.

Discontinue pseudoephedrine exposure

• Given Adam’s substantial change from his historical blood pressure and the availability of safer alternatives for allergic rhinitis, Allegra-D should be discontinued.

• If antihistamine therapy remains necessary, fexofenadine alone could be continued because it does not contain the sympathomimetic decongestant responsible for the cardiovascular concern.

• For persistent nasal congestion, an intranasal corticosteroid may provide more effective control of allergic rhinitis without the systemic sympathomimetic effects associated with oral pseudoephedrine.

Reassess blood pressure before committing to long-term antihypertensive escalation

• Blood pressure should be reassessed after pseudoephedrine withdrawal using repeated standardized office measurements and preferably home or ambulatory blood pressure monitoring.

• If blood pressure returns toward Adam’s previous baseline, this would support a medication-related contribution and reduce the likelihood that additional antihypertensive therapy is necessary.

• If hypertension persists despite withdrawal, primary hypertension or another secondary cause should then be evaluated and treated according to cardiovascular risk and contemporary hypertension guidelines.

Reassess recently introduced antihypertensive therapy

• The ongoing need for lisinopril and amlodipine should be reconsidered after pseudoephedrine has been removed and blood pressure reassessed.

• Antihypertensive therapy should not be withdrawn automatically; rather, medications should be reviewed sequentially with appropriate blood pressure monitoring. If blood pressure becomes excessively low following pseudoephedrine withdrawal, antihypertensive doses may require reduction or discontinuation.

Patient education

• Adam should be advised to check the active ingredients of over-the-counter cold and allergy preparations, particularly products labelled with a “D,” which commonly indicates the addition of a decongestant.

• He should also be counselled that medications available without prescription can still have clinically important cardiovascular effects and should be included during medication reconciliation.

Clinical Rationale and Ramifications

This case illustrates how a seemingly routine over-the-counter medication can initiate a clinically important prescribing cascade. Pseudoephedrine effectively relieves nasal congestion through systemic sympathomimetic activity, but the same pharmacologic mechanism can increase vascular tone and contribute to elevated blood pressure, particularly in susceptible individuals.

Failure to recognize the temporal association between Allegra-D initiation and Adam’s blood pressure elevation resulted in the addition and subsequent intensification of antihypertensive therapy. If the underlying medication-related cause remained unidentified, Adam could be exposed unnecessarily to long-term polypharmacy and antihypertensive adverse effects, including dizziness, orthostatic hypotension, falls, electrolyte abnormalities, and renal complications.

An additional concern arises if pseudoephedrine is eventually stopped while both antihypertensive medications are continued. Removal of the sympathomimetic stimulus could lower blood pressure substantially, potentially exposing the patient to iatrogenic hypotension.

Importantly, pseudoephedrine does not invariably produce clinically significant hypertension in every patient; average blood-pressure increases observed in controlled studies are generally modest. Therefore, the appropriate clinical approach is to establish temporality, withdraw the suspected contributor when feasible, and reassess blood pressure objectively rather than automatically attributing every elevated reading to pseudoephedrine.

This case reinforces an important principle of medication safety: when a new clinical abnormality develops after a medication is introduced, the medication list should be reviewed before another drug is added to treat the new problem. Identifying and removing a reversible pharmacological cause can prevent unnecessary treatment escalation and reduce medication-related harm.